Optimizing Prostate Cancer Care Moving Beyond PSA
Robert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment.
Read More
Radiation Safety Measures and Precautions for Prostate Cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.
Understanding Multidisciplinary Care for Advanced Prostate Cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses that patients with advanced prostate cancer benefit from a multidisciplinary care team.
Advancing the Perioperative Management of Bladder Cancer
Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.
Risk Stratification Aids Oncologists in the Management of Frontline RCC
According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.
IO and Targeted Therapies Advance the Metastatic Urothelial Cancer Treatment Landscape
In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.
